纳武利尤单抗联合伊匹木单抗一线治疗转移性葡萄膜黑色素瘤的II期研究
西班牙黑色素瘤多学科组开展的开放标签、多中心、单臂II期研究,纳入52例不适合肝切除的初治转移性葡萄膜黑色素瘤患者,评估纳武利尤单抗联合伊匹木单抗一线治疗的12个月总生存率,结果为51.9%(95%CI 38.3-65.5),中位OS 12.7个月、中位PFS 3.0个月,毒性可控。
要点
- 12个月OS率为51.9%(95%CI 38.3-65.5),中位OS 12.7个月。
- 中位PFS为3.0个月,较高LDH值与PFS相关。
- 最常见疗效为疾病稳定(51.9%),毒性可控。
核心结论
- 纳武利尤单抗联合伊匹木单抗一线治疗转移性葡萄膜黑色素瘤较历史化疗基准显示OS的适度改善,毒性可控。
研究设计与样本
- 西班牙黑色素瘤多学科组(GEM)领导的单臂、开放标签、多中心II期试验(GEM-1402)。
- 纳入52例年龄>18岁、组织学确诊的初治转移性葡萄膜黑色素瘤患者,ECOG-PS 0/1,不适合肝切除。
- 纳武利尤单抗1 mg/kg每3周联合伊匹木单抗3 mg/kg每3周诱导4次,继以纳武利尤单抗3 mg/kg每2周直至进展、毒性或退出。
- 主要终点为12个月OS,每6周按RECIST v1.1评估OS、PFS和客观缓解率并评估安全性。
主要发现
- 患者中位年龄59岁(范围26-84岁),肝M1者占78.8%,肝外M1者占56%,LDH升高者占32%。
- 疾病稳定为最常见疗效(51.9%)。
- 12个月OS率为51.9%(95%CI 38.3-65.5),中位OS为12.7个月,中位PFS为3.0个月。
- PFS受较高LDH值影响。
关键数值与推荐
- 主要终点12个月OS率为51.9%(95%CI 38.3-65.5)。
- 中位OS为12.7个月,中位PFS为3.0个月。
- 肝M1占78.8%、肝外M1占56%、LDH升高占32%,疾病稳定占51.9%。
临床怎么用
- 对于不适合肝切除的初治转移性葡萄膜黑色素瘤患者,可考虑纳武利尤单抗联合伊匹木单抗一线治疗。
- 治疗期间需关注LDH水平,较高LDH值与PFS相关。
- 该方案毒性可控,可按诱导后纳武利尤单抗维持的给药模式管理。
局限性
- 为单臂II期试验,无随机对照,结论需更大样本验证。
- 样本量52例,随访与疗效数据有限。
- 原文未报告免疫相关不良事件的具体发生率与分级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to assess the efficacy of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligible for liver resection. METHODS: This was a single-arm, phase II trial led by the Spanish Multidisciplinary Melanoma Group (GEM) on nivo plus ipi for systemic treatment-naïve patients of age > 18 years, with histologically confirmed MUM, Eastern Cooperative Oncology Group-PS 0/1, and confirmed progressive metastatic disease (M1). Nivo (1 mg/kg once every 3 weeks) and ipi (3 mg/kg once every 3 weeks) were administered during four inductions, followed by nivo (3 mg/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal. The primary end point was 12-month OS. OS, progression-free survival (PFS), and overall response rate were evaluated every 6 weeks using RECIST (v1.1). Safety was also evaluated. Logistic regression and Cox proportional hazard models comprising relevant clinical factors were used to evaluate the potential association with response to treatment and survival. Cytokines were quantified in serum samples for their putative role in immune modulation/angiogenesis and/or earlier evidence of involvement in immunotherapy. RESULTS: A total of 52 patients with a median age of 59 years (range, 26-84 years) were enrolled. Overall, 78.8%, 56%, and 32% of patients had liver M1, extra-liver M1, and elevated lactate dehydrogenase. Stable disease was the most common outcome (51.9%). The primary end point was 12-month OS, which was 51.9% (95% CI, 38.3 to 65.5). The median OS and PFS were 12.7 months and 3.0 months, respectively. PFS was influenced by higher LDH values. CONCLUSIONS: Nivo plus ipi in the first-line setting for MUM showed a modest improvement in OS over historical benchmarks of chemotherapy, with a manageable toxicity profile.
引用
- Piulats JM, Espinosa E, de la Cruz Merino L, et al. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol. 2021. PMID: 33417511. doi:10.1200/JCO.20.00550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。